As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...

The latest health news highlights global mental health initiatives, legal disputes over drug patents, setbacks in depression drug trials, and advisories on alcohol consumption risks. China's Health ...

The lawsuit was brought against the FDA after the agency declared an end to the shortage that allowed pharmacies to sell compound versions of the popular weight loss drugs, but Eli Lilly said it ...

Axios Visuals The number of prescriptions for GLP-1 drugs jumped roughly 10% in 2024, according to insurance claims data provided to Axios by health analytics company PurpleLab. Why it matters: The ...